Inhibition of Autoimmune Diabetes in NOD Mice by miRNA Therapy

Autoimmune destruction of the pancreatic islets in Type 1 diabetes is mediated by both increased proinflammatory (Teff) and decreased regulatory (Treg) T lymphocytes resulting in a significant decrease in the Treg:Teff ratio. The non-obese diabetic (NOD) mouse is an excellent in vivo model for testing potential therapeutics for attenuating the decrease in the Treg:Teff ratio and inhibiting disease pathogenesis. Here we show for the first time that a bioreactor manufactured therapeutic consisting of a complex of miRNA species (denoted as TA1) can effectively reset the NOD immune system from a proinflammatory to a tolerogenic state thus preventing or delaying autoimmune diabetes. Treatment of NOD mice with TA1 resulted in a systemic broad-spectrum upregulation of tolerogenic T cell subsets with a parallel downregulation of Teff subsets yielding a dramatic increase in the Treg:Teff ratio. Moreover, the murine-derived TA1 was highly effective in the inhibition of allorecognition of HLA-disparate human PBMC. TA1 demonstrated dose-responsiveness and exhibited equivalent or better inhibition of allorecognition driven proliferation than etanercept (a soluble TNF receptor). These findings demonstrate that miRNA-based therapeutics can effectively attenuate or arrest autoimmune disease processes and may be of significant utility in a broad range of autoimmune diseases including Type 1 diabetes.

• Publication year

  2015

• Venue

  PLoS ONE

• Publication date

  2015-12-16

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1371/journal.pone.0145179PMID 26674203PMCID 4692265
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Maintenance of immune tolerance by Foxp3+ regulatory T cells requires CD69 expression.

  2014cited by this paper
• Comparative efficacy of blood cell immunocamouflage by membrane grafting of methoxypoly(ethylene glycol) and polyethyloxazoline.

  2014cited by this paper
• MicroRNAs and cancer therapy - from bystanders to major players.

  2013cited by this paper
• Correlation between the Frequency of Th17 Cell and the Expression of MicroRNA-206 in Patients with Dermatomyositis

  2013cited by this paper
• Current and Future Applications of Immunological Attenuation via Pegylation of Cells and Tissue

  2012cited by this paper
• Dendritic Cells With TGF-&bgr;1 and IL-2 Differentiate Naive CD4+ T Cells Into Alloantigen-Specific and Allograft Protective Foxp3+ Regulatory T Cells

  2012cited by this paper
• Circulating Levels of MicroRNA from Children with Newly Diagnosed Type 1 Diabetes and Healthy Controls: Evidence That miR-25 Associates to Residual Beta-Cell Function and Glycaemic Control during Disease Progression

  2012cited by this paper
• Immunomodulation of Antigen Presenting Cells Promotes Natural Regulatory T Cells That Prevent Autoimmune Diabetes in NOD Mice

  2012cited by this paper
• The potential utility of methoxypoly(ethylene glycol)-mediated prevention of rhesus blood group antigen RhD recognition in transfusion medicine.

  2012cited by this paper
• Pancreatic islet expression of chemokine CCL2 suppresses autoimmune diabetes via tolerogenic CD11c+ CD11b+ dendritic cells

  2012cited by this paper
• The suppressive effect of CD25+Treg cells on Th1 differentiation requires cell—cell contact partially via TGF‐β production

  2011cited by this paper
• Diabetes mellitus, a microRNA-related disease?

  2011cited by this paper
• A multivalent vaccine for type 1 diabetes skews T cell subsets to Th2 phenotype in NOD mice

  2011cited by this paper
• Induction of immunotolerance via mPEG grafting to allogeneic leukocytes.

  2011cited by this paper
• Anti-CD3 therapy permits regulatory T cells to surmount T cell receptor–specified peripheral niche constraints

  2010cited by this paper
• MicroRNA-based Cancer Therapeutics: Big Hope from Small RNAs.

  2010cited by this paper
• microRNAs: critical regulators in Th17 cells and players in diseases

  2010cited by this paper
• A short pulse of IL-4 delivered by DCs electroporated with modified mRNA can both prevent and treat autoimmune diabetes in NOD mice.

  2010influential reference
• Immunocamouflage: the biophysical basis of immunoprotection by grafted methoxypoly(ethylene glycol) (mPEG).

  2010cited by this paper
• Use of nonobese diabetic mice to understand human type 1 diabetes.

  2010cited by this paper
• Identification of miR-34a as a potent inhibitor of prostate cancer progenitor cells and metastasis by directly repressing CD44

  2010cited by this paper
• Immunotherapy of type 1 diabetes: where are we and where should we be going?

  2010cited by this paper
• IL-17 and Th17 Cells.

  2009cited by this paper
• MicroRNAs: Target Recognition and Regulatory Functions

  2009cited by this paper
• How punctual ablation of regulatory T cells unleashes an autoimmune lesion within the pancreatic islets.

  2009cited by this paper
• Regulatory T-Cells Protect From Type 1 Diabetes After Induction by Coxsackievirus Infection in the Context of Transforming Growth Factor-β

  2008cited by this paper
• The defect in T-cell regulation in NOD mice is an effect on the T-cell effectors

  2008cited by this paper
• IL-6 controls Th17 immunity in vivo by inhibiting the conversion of conventional T cells into Foxp3+ regulatory T cells

  2008cited by this paper
• Functional Waning of Naturally Occurring CD4+ Regulatory T-Cells Contributes to the Onset of Autoimmune Diabetes

  2008cited by this paper
• Most mammalian mRNAs are conserved targets of microRNAs.

  2008influential reference
• Induction and effector functions of TH17 cells

  2008cited by this paper
• Granulocyte-Macrophage Colony-Stimulating Factor Prevents Diabetes Development in NOD Mice by Inducing Tolerogenic Dendritic Cells that Sustain the Suppressive Function of CD4+CD25+ Regulatory T Cells1

  2007cited by this paper
• Th17 cells: effector T cells with inflammatory properties.

  2007cited by this paper
• The evolution of gene regulation by transcription factors and microRNAs

  2007cited by this paper
• Comparative Analysis of Polymer and Linker Chemistries on the Efficacy of Immunocamouflage of Murine Leukocytes

  2006cited by this paper
• Autoimmune diabetes onset results from qualitative rather than quantitative age-dependent changes in pathogenic T-cells.

  2005cited by this paper
• The role of regulatory T cell defects in type I diabetes and the potential of these cells for therapy.

  2005cited by this paper
• The NOD mouse: a model of immune dysregulation.

  2005influential reference
• Modulation of Hepatitis C Virus RNA Abundance by a Liver-Specific MicroRNA

  2005cited by this paper
• Conserved seed pairing, often flanked by adenosines, indicates that thousands of human genes are microRNA targets.

  2005cited by this paper
• Defective suppressor function in CD4(+)CD25(+) T-cells from patients with type 1 diabetes.

  2005cited by this paper
• The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure

  2003cited by this paper
• Dynamics of Pathogenic and Suppressor T Cells in Autoimmune Diabetes Development

  2003influential reference
• The role of T-cells in the pathogenesis of Type 1 diabetes: From cause to cure

  2003cited by this paper
• Immunocamouflage: prevention of transfusion-induced graft-versus-host disease via polymer grafting of donor cells.

  2003cited by this paper
• Clinical outcomes and insulin secretion after islet transplantation with the Edmonton protocol.

  2001cited by this paper
• B7/CD28 costimulation is essential for the homeostasis of the CD4+CD25+ immunoregulatory T cells that control autoimmune diabetes.

  2000cited by this paper
• Islet Transplantation in Seven Patients with Type 1 Diabetes Mellitus Using a Glucocorticoid-Free Immunosuppressive Regimen

  2000cited by this paper
• Islet transplantation in seven patients with type 1 diabetes mellitus using a glucocorticoid-free immunosuppressive regimen.

  2000cited by this paper
• Stealth cells: prevention of major histocompatibility complex class II-mediated T-cell activation by cell surface modification.

  1999cited by this paper
• The NOD mouse model of type 1 diabetes: As good as it gets?

  1999cited by this paper
• CD40 and CD154 in cell-mediated immunity.

  1998cited by this paper
• Immunology of IDDM

  1997cited by this paper
• CD40 ligand-CD40 interactions are necessary for the initiation of insulitis and diabetes in nonobese diabetic mice.

  1997cited by this paper
• Beta cell mass and growth after syngeneic islet cell transplantation in normal and streptozocin diabetic C57BL/6 mice.

  1993cited by this paper

• Insights into the development of insulin-producing cells: Precursors correlated involvement of microRNA panels.

  2024cites this paper
• Identification of a potent regulatory T cell epitope in factor V that modulates CD4+ and CD8+ memory T cell responses.

  2021cites this paper
• Differential Leukocyte MicroRNA Responses Following Pan T Cell, Allorecognition and Allosecretome-Based Therapeutic Activation

  2021cites this paper
• Immune Tolerance-Adjusted Personalized Immunogenicity Prediction for Pompe Disease

  2021cites this paper
• Biological Modulation of the Treg:Teff Ratio: From Immunosuppression to Immunoactivation

  2020influential citation
• Modulating the T Lymphocyte Immune Response via Secretome Produced miRNA: From Tolerance Induction to the Enhancement of the Anticancer Response

  2019cites this paper
• Differential Leukocyte miRNA Responses Following Pan T Cell, Allorecognition and Allosecretome-Based Therapeutics Activation

  2019influential citation
• Enhancing the pro-inflammatory anti-cancer T cell response via biomanufactured, secretome-based, immunotherapeutics.

  2019cites this paper
• Inhibition of allogeneic cytotoxic T cell (CD8+) proliferation via polymer-induced Treg (CD4+) cells.

  2017cites this paper
• miRNA-36 inhibits KSHV, EBV, HSV-2 infection of cells via stifling expression of interferon induced transmembrane protein 1 (IFITM1)

  2017cites this paper
• Recent Advances on the Role of microRNAs in both Insulin Resistance and Cancer.

  2017cites this paper